10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off
10x Genomics, Inc. (NASDAQ: TXG) — a leading player in single-cell and spatial biology — is back in the spotlight after a sharp share-price drop on 11 December 2025. A high-profile analyst downgrade from Citigroup hit the stock the same morning, even as the company pushes forward with ambitious AI collaborations and cancer atlas projects that could shape its long-term growth story. MarketScreener+2StockStory+2 Below is a detailed look at what moved TXG today, how Wall Street views the stock heading into 2026, and what recent partnerships and earnings say about its future. Key Takeaways 10x Genomics Stock Today: December 11,